TPST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Tempest Therapeutics Inc (TPST) does not present a compelling buy opportunity for a beginner long-term investor with $50,000-$100,000 available for investment. The stock lacks strong positive catalysts, has weak financial performance, and no significant trading signals or trends. While the recent analyst upgrade is a positive sign, the company's financial struggles and lack of clear technical or options-based momentum suggest holding off on investment at this time.
The MACD is slightly positive but contracting, indicating weak momentum. RSI is neutral at 35.538, showing no clear overbought or oversold conditions. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its pivot level of 2.336, with weak support and resistance levels. Overall, technical indicators do not suggest a strong buy signal.
The recent analyst upgrade by H.C. Wainwright highlights the acquisition of Factor Bioscience's CAR-T programs as a strategic move to extend the company's cash runway and expand its pipeline with a clinically de-risked asset. This demonstrates potential long-term growth opportunities.
The company's financial performance is weak, with significant YoY declines in net income (-66.74%) and EPS (-85.15%). Additionally, there is no recent news, no significant trading trends from hedge funds or insiders, and no congress trading data to indicate increased interest or confidence in the stock.
In Q3 2025, the company reported no revenue growth (0% YoY) and a significant drop in net income to -$3,511,000 (-66.74% YoY). EPS also fell sharply to -0.79 (-85.15% YoY). Gross margin remains at 0%, indicating no profitability.
H.C. Wainwright upgraded the stock to Buy with an $11 price target, citing the acquisition of Factor Bioscience's CAR-T programs as a strategic move to extend cash runway and expand the pipeline. However, the upgrade is based on long-term potential rather than immediate performance improvements.
